MedPath

Sub-total Parathyroidectomy Reduces Vascular Calcification in Haemodialysis Patients

Not Applicable
Conditions
Hemodialysis
Registration Number
NCT01140490
Lead Sponsor
Guangdong Provincial People's Hospital
Brief Summary

The aim of this study was to evaluate whether successful sub-total parathyroidectomy retards cardiovascular calcification in patients with hemodialysis and to investigate the mechanism .

Detailed Description

Hyperparathyroidism (PHPT) in patients with end-stage renal disease have been shown to have an increased morbidity and mortality mainly due to cardiovascular disease. The precise mechanism of cardiovascular disease in PHPT is not well understood . The excess in cardiovascular mortality is significantly and independently related to serum calcium, the connection between the biochemical disturbances and the cardiovascular disorders in PHPT patients is not necessarily a cause-and-effect relationship. Indeed, the impact of surgical cure of hyperparathyroidism on cardiovascular risk factors and mortality is controversial. Some studies suggest that cardiovascular risk markers remained unaltered after Sub-total Parathyroidectomy.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • The patients receiving hemodialysis treatment, with elevated intact parathyroid hormone (iPTH) levels > 800pg/ml on two or more occasions.
  • Patients with parathyroid nodular or diffuse hyperplasia identified by ultrasound imaging or radioisotope scan.
Exclusion Criteria
  • Patients with significant background valvular heart disease
  • Patients who are unfit for general anaesthesia
  • Patients with acute myocardial infarction within recent two months
  • Patients with poor general condition
  • Patients with plans for living related kidney transplant within 1 year
  • Patients with previous history of parathyroidectomy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in vascular calcium scores12 months
Secondary Outcome Measures
NameTimeMethod
Change in left ventricular systolic and diastolic function12 months

Trial Locations

Locations (1)

Guangdong General Hospital

🇨🇳

Guangzhou, Guangdong, China

Guangdong General Hospital
🇨🇳Guangzhou, Guangdong, China
Liu shuangxin, MD and Phd
Contact
8602083827812
mplsxi@yahoo.com.cn

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.